New Remedy for Moderate & Severe Covid

December 13, 2020

Covid Update

Baricitinib Plus Remdesivir for Hospitalized Adults with COVID-19 : The New England journal of Medicine

India

healthysoch

New Delhi, December 13, 2020 :

Salient Features

  • Severe coronavirus disease 2019 (Covid-19) is associated with Dysregulated inflammation which leads to severe disease •
  • In A double-blind, Randomized, placebo-controlled trial received Baricitinib with and without Remdesivir with a primary out come of time to recovery
  • The trial was conducted on 1033 patients in eight countries. Patients receiving Baricitinib had a median time to recovery of 7 days (95% confidence interval [CI], 6 to 8), as compared with 8 days (95% CI, 7 to 9) with control( P=0.03). There was 30% higher odds of improvement in clinical status at day 15 with combination therapy.
  • In patients requiring high flow oxygen the recovery time was 8 days in Baricitinib as compared to 18 days in control group
  • The 28-day mortality was 5.1% in the combination group as compared to 7.8% ( statistically insignificant)
  • Serious adverse events were less frequent in the combination group than in the control group (16.0% vs. 21%).

According to Dr G C Khilani, With better understanding of Covid, the mortality is consistently coming down, however, there is very little contribution of pharmacotherapy except corticosteroids and Remdesivir. All the drugs including Hydroxychloroquine, Azithromycin, Doxycycline and ivermectin have not shown clinical benefit in properly conducted Randomized trials.

Among antivirals Remdesivir has shown convincing clinical benefit (ACTT-1 trial). We have all observed in clinical practice that Dysregulated hyperimmune response causes enhanced severity leading to respiratory failure and death. It that case mitigating the immune response and preventing a Hyperinflammatory state is likely to improve outcome. In a recent study (NEJM, 10th Dec ; N Engl J Med 2020; 383:2387-2388) Tociluzimab was found to be ineffective in improving outcome.

Baricitinib is a selective inhibitor of Janus kinase (JAK) 1 and 2, is administered orally. It inhibits the intracellular signalling pathway of cytokines known to be elevated in severe Covid-19, including interleukin-2, interleukin-6, interleukin10, interferon-γ, and granulocyte–macrophage colony-stimulating factor; acts against SARS-CoV-2 through the impairment of AP2-associated protein kinase 1 and the prevention of SARS-CoV-2 cellular entry and infectivity; and improves lymphocyte counts in patients with Covid

This large (1033 patients) Randomized trial conducted in 8 countries have shown that the combination of Remdesivir and Baricitinib significantly reduced recovery time . Also patients(with a baseline ordinal score of 6) who received combination treatment were more likely to have clinical improvement at day 15 (odds ratio, 2.2; 95% CI, 1.4 to 3.6). The survival rate and the time-to death analyses favoured combination treatment. The mortality was lower in combination therapy (5.1% v/s 7.8%) which was statistically insignificant.There were no adverse effects. A faster recovery would presumably lead to lower chances of secondary infections and improved outcome.

This study is a novel hope in enhancing the armamentarium in the management of Covid which has shattered our lives. I think, this may not have as promising effect as steroids, however, it would certainly add to management of serious disease for control of Dysregulated hyperimmune syndrome . Another study with the same molecule is `ongoing’ and we hope to have results soon.

Author : G C Khilnani Chairman, PSRI Institute of Pulmonary, Critical care and Sleep Medicine, PSRI Hospital, New Delhi. Formerly, Professor and Head Dept of Pulmonary Critical care and Sleep Medicine, AIIMS, New Delhi-110029

healthysoch

Stay informed with the latest news from HealthySoch. Sign up today for exclusive insights and updates!

We promise we never spam!

Leave a Reply

Your email address will not be published.

Health Tips

Dr. T S Kler Padma Bhushan Awardee
MD, DM, MRCP, FRCP(U.K), FACC, D.Sc
Chairman – Fortis Heart Institute Gurugram

Precautions to avoid Corona Virus:

  1. Stay home as far as possible.
  2. Wash hands with soap and water frequently.
  3. Keep distance from people even your home members.
  4. Keep atleast 1-2 metres away from anybody coughing.
  5. Don’t touch your face, nose and mouth.

 

Dr. K.K Says

Archives

MonTueWedThuFriSatSun
    123
45678910
18192021222324
25262728293031
       
   1234
567891011
12131415161718
26272829   
       
891011121314
293031    
       
    123
45678910
11121314151617
25262728293031
       
  12345
6789101112
13141516171819
27282930   
       
      1
2345678
9101112131415
16171819202122
3031     
     12
17181920212223
24252627282930
31      
   1234
567891011
12131415161718
2627282930  
       
1234567
891011121314
22232425262728
293031    
       
     12
3456789
17181920212223
24252627282930
       
  12345
6789101112
       
  12345
13141516171819
2728     
       
      1
9101112131415
3031     
   1234
567891011
       
282930    
       
    123
45678910
       
  12345
27282930   
       
      1
3031     
    123
11121314151617
       
28      
       
2930     
       
    123
       
       
       
      1
9101112131415
3031     
     12
3456789
10111213141516
17181920212223
242526272829 
       
  12345
13141516171819
2728293031  
       
      1
23242526272829
3031     
    123
       
    123
25262728   
       
78910111213
28293031   
       
293031    
       
14151617181920
28293031   
       
   1234
567891011
       
   1234
567891011
262728    
       
891011121314
293031    
       
    123
18192021222324
25262728293031
       
  12345
27282930   
       
      1
2345678
16171819202122
3031     
    123
45678910
18192021222324
       
28293031   
       
     12
31      
   1234
       
  12345
6789101112
       
HealthySoch

Don't Miss

Institutions liability is much more than treating doctors liability

healthysoch New Delhi, July 12, 2019 : The Hon’ble Supreme

A high risk Bypass Grafting surgery blessed a 92 year old with a new life at Jaypee Hospital

“She was a known patient of coronary heart disease and had